Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06690086 · ClinicalTrials.gov registry record

DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer

A clinical trial of Skin Cancer, sponsored by DermaSensor.

Completed
Registry status
1,028
Enrollment target
1
Study location

NCT06690086: Completed study of Skin Cancer, sponsored by DermaSensor.

NCT06690086 is a study of Skin Cancer that has completed, run by DermaSensor. The registered enrollment target is 1,028 participants, above the 438-participant average among 40 other Skin Cancer trials with a reported enrollment target (135% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06690086, a study of Skin Cancer, has completed, sponsored by DermaSensor.

COMPLETED
Registry status
1,028 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the clinical validity of the proprietary DermaSensor Elastic Scattering Spectroscopy (ESS) device and classifier algorithm to support assessment of skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in the primary care setting.

Conditions Studied

Interventions

  • PROCEDURE Lesion biopsy
  • DEVICE DermaSensor Device Use

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 1,028 participants
Start Date 2020-08-17
Est. Completion 2021-12-09
DermaSensor

2 total trials

What the finished NCT06690086 record still lists

NCT06690086 is an observational study that tracks outcomes without assigning an intervention. Its 1,028 participants enrollment target places it among the larger protocols in the corpus, above the 438-participant average among 40 other Skin Cancer trials with a reported enrollment target (135% higher).

The record links to 1 condition, with Skin Cancer appearing as the primary indexed condition, and to 2 interventions - of which Lesion biopsy is the first listed.

NCT06690086 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06690086 about?

NCT06690086 is a clinical study titled "DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer". The purpose of this study is to evaluate the clinical validity of the proprietary DermaSensor Elastic Scattering Spectroscopy (ESS) device and classifier algorithm to support assessment of skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in the primary care s...

What is the current status of trial NCT06690086?

This trial is currently completed. The enrollment target is 1,028 participants. The study started on 2020-08-17. Estimated completion is 2021-12-09.

What conditions does trial NCT06690086 study?

This clinical trial studies the following conditions: Skin Cancer.

What interventions are being tested in trial NCT06690086?

The interventions under investigation include: Lesion biopsy (PROCEDURE), DermaSensor Device Use (DEVICE).

Who is sponsoring clinical trial NCT06690086?

This trial is sponsored by DermaSensor, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06690086 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Skin Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06690086's enrollment target sits among peer trials

1,028 6th of 40 higher than 35 of 40 other Skin Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Skin Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06080698 · 1,030 participants · NA

    Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

  • NCT02200276 · 1,025 participants · NA

    Influenza Immunization in Adults Over Age 75

  • NCT02296450 · 1,025 participants

    Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

  • NCT07084363 · 1,032 participants · NA

    Quantitative Versus qUAlitative NeuromoniToring of neUroMuscular Block for Non-cardiothoracic Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06690086, the US trial registry maintained by the National Library of Medicine. NCT06690086 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.